PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K

What Happened

• Pacific Biosciences of California, Inc. announced that its board approved an amendment to the company’s 2020 Equity Incentive Plan on April 21, 2026 (recommended by the compensation committee) to reserve an additional 16,000,000 shares of common stock for issuance under the plan. Stockholders approved the amendment at the company’s virtual Annual Meeting on June 3, 2026. The amended plan text is filed as Exhibit 10.1 to the Form 8‑K (filed June 4, 2026).

Key Details

• Board approval date: April 21, 2026 (subject to stockholder approval).
• Stockholder approval: June 3, 2026 (Annual Meeting, held virtually).
• Additional shares reserved: 16,000,000 shares of common stock for issuance under the 2020 Equity Incentive Plan.
• Amended 2020 Equity Incentive Plan is included as Exhibit 10.1 to the 8‑K.

Why It Matters

• The increase expands the pool of shares available for equity awards (options, RSUs, etc.), which the company uses for employee and executive compensation, retention, and recruitment. That can lead to future share issuance and potential dilution for existing shareholders as awards are granted and vested. Investors should review the amended plan (Exhibit 10.1) and the company’s proxy materials for details on award types, vesting, and potential dilution.